Logo for Saniona

Saniona Investor Relations Material

Latest events

Logo for Saniona

Q3 2023

30 Nov, 2023
Logo for Saniona

Q2 2023

31 Aug, 2023
Access the full event backlog
Slides, Transcripts, and Reports from over 8,000 public companies
Saniona AB engages in the research, development, and commercialization of treatments for the central nervous system. The company's products include Tesofensine, a monoamine reuptake inhibitor; Tesomet, a fixed dose combination of tesofensine and metoprolol; SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. Saniona AB (publ) has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS